Tvardi Therapeutics reports larger-than-expected Q4 net loss

Tvardi Therapeutics

31/03/2026 21:12

Overview

US biopharma's Q4 net loss narrowed but missed analyst expectations

R&D expenses fell on lower TTI-101 clinical costs; G&A expenses rose due to merger fees

Outlook

Company expects cash runway to fund operations into Q4 2026, covering clinical readouts

Result Drivers

R&D COSTS SHIFT - Lower Q4 research and development expenses were mainly due to declining clinical costs for TTI-101, partially offset by increased spending on TTI-109 development

MERGER-RELATED FEES - Higher general and administrative expenses in Q4 were mainly due to increased legal, accounting and audit fees following the merger with Cara Therapeutics and public company filings

Company press release: ID:nGNX7Z8tyv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.78
Q4 Net Income
Miss
-$7.30 mln
-$5.67 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tvardi Therapeutics Inc is $10.00, about 212.5% above its March 30 closing price of $3.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)